| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S87890-2mg |
≥98% | ￥450.00 |
货期：3-5天 | - | - | - | - |
|
S87890-5mg |
≥98% | ￥860.00 |
货期：3-5天 | - | - | - | - |
|
S87890-10mg |
≥98% | ￥1200.00 |
货期：3-5天 | - | - | - | - |
|
S87890-25mg |
≥98% | ￥1700.00 |
货期：3-5天 | - | - | - | - |
|
S87890-50mg |
≥98% | ￥3200.00 |
货期：3-5天 | - | - | - | - |
|
S87890-100mg |
≥98% | ￥4200.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | ROCK1:7 nM (IC50);RSK1:398 nM (IC50);p70S6K:1000 nM (IC50);ROCK; S6Kinase; mTOR | ||||||||||||||||||||
| 体内研究： | GSK-25 (Rat aorta IC50=256 nM) is profiled in a spontaneously hypertensive rat (SHR) model of hypertension. At 30 mg/kg (p.o.), GSK-25 induces a 25 mmHg (t=3 hours) drop in blood pressure. GSK-25 has promising oral bioavailability (49% in male Sprague-Dawley rats and 19% in monkey), good half-life (1.8 hours in rat and 2.2 hours in monkey) | ||||||||||||||||||||
| 参考文献： | 1. Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51(21):6631-4. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京